Home › Funds › Assenagon Asset Management S.A. › VRTX

Assenagon Asset Management S.A. position in VRTX

VERTEX PHARMACEUTICALS INC · Health Care

Assenagon Asset Management S.A. reported holding 1,219,311 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$637.5M, representing 0.78% of its reported portfolio and ranking #24 among its reported holdings. Assenagon Asset Management S.A. has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)1.22M sh
Reported value held$637.47M
Portfolio Weight0.78%
First reportedQ3 2023
Last changeAdd
Updated2026-10-15

Last updated: 2026-10-15 · Source: SEC EDGAR Form 13F-HR

How Assenagon Asset Management S.A.'s VRTX position evolved

Assenagon Asset Management S.A. first disclosed a stake in VRTX in Q3 2023 at 202,231 shares (US$70.3M). The position peaked in Q3 2026 at 1,219,311 shares, worth US$637.5M. Across 13 filings, Assenagon Asset Management S.A. increased the stake 9 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,219,311 shares valued at US$637.5M — an increase of 459,747 shares quarter over quarter.. Notable position changes include a 224% increase in Q3 2024 (shares fell 13% over the following quarter), a 169% increase in Q4 2024 (shares rose 20% over the following quarter), a 215% increase in Q3 2025 (shares rose 16% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 202.23K $70.32M New
Q4 2023 296.15K $120.50M Add
Q1 2024 323.09K $135.05M Add
Q2 2024 96.19K $45.09M Reduce
Q3 2024 311.64K $144.94M Add
Q4 2024 839.67K $338.14M Add
Q1 2025 208.14K $100.91M Reduce
Q2 2025 242.75K $108.07M Add
Q3 2025 763.70K $299.10M Add
Q4 2025 832.85K $377.58M Add
Q1 2026 537.25K $239.90M Reduce
Q2 2026 759.56K $377.30M Add
Q3 2026 1.22M $637.47M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRTX and 13F data

VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 33 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$12.97B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRTX

All VRTX fund holders →

FAQ

How long has Assenagon Asset Management S.A. held VRTX?

Assenagon Asset Management S.A. has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Assenagon Asset Management S.A.'s current position in VRTX?

As of Q3 2026, Assenagon Asset Management S.A. holds 1.22M shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $637.47M, representing 0.78% of its reported portfolio and ranking #24.

Has Assenagon Asset Management S.A. been buying or selling VRTX?

In the latest 13F filing (Q3 2026), Assenagon Asset Management S.A. increased its position in VRTX. The position peaked in Q3 2026 at 1.22M shares.

Which other funds hold VRTX?

Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 33 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.